Literature DB >> 26715173

Practical issues in the diagnosis of serous carcinoma of the endometrium.

Sonia Gatius1, Xavier Matias-Guiu1.   

Abstract

Serous carcinoma (SC) represents ~10% of endometrial carcinomas, but is responsible for almost 40% of cancer deaths. This article reviews the main pathological features, differential diagnosis, and the usefulness of molecular pathology and immunohistochemistry in its diagnosis. Most helpful features for the diagnosis include: irregularly shaped and sized papillae, slit-like spaces, cell stratification and budding, highly atypical cells, architectural and cytological discordance in pseudoglandular tumors, as well as lack of endometrioid features. SC shows typically a predominant papillary growth, which is also found in some subtypes of endometrioid carcinoma of the endometrium (EEC). Distinction is easy when attention is paid to the presence of diffuse marked nuclear pleomorphism, but also to the complex papillary architecture. SC may also show a solid or pseudoglandular patterns, and in these cases differential diagnosis may be difficult with EEC grade 3. Moreover, a high proportion of SC may exhibit clear cells, and, thus, may be confused with clear cell carcinoma. Finally, it is sometimes difficult to distinguish mixed SC-EEC, from SC that combines papillary and pseudoglandular growths. Although there is not a single immunohistochemical marker for distinguishing SC from its mimickers, some antibodies are useful (p53, p16, IMP2, and IMP3), particularly when used in combination. Diagnosis of SC may be even more problematic in small biopsies; a diagnosis of high-grade endometrial carcinoma, SC component can not be excluded, is acceptable as a managerial approach, so it could be taken into account at the time of final surgery.

Entities:  

Mesh:

Year:  2016        PMID: 26715173     DOI: 10.1038/modpathol.2015.141

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  82 in total

1.  Uterine Endometrioid Carcinoma with Small Nonvillous Papillae: An Analysis of 26 Cases of a Favorable-Prognosis Tumor To Be Distinguished from Serous Carcinoma.

Authors:  Shawn K. Murray; Robert H. Young; Robert E. Scully
Journal:  Int J Surg Pathol       Date:  2000-10       Impact factor: 1.271

2.  Pure compared with mixed serous endometrial carcinoma: two different entities?

Authors:  Thijs Roelofsen; Maaike A P C van Ham; Johanna M Wiersma van Tilburg; Saskia F Zomer; Mijke Bol; Leon F A G Massuger; Johan Bulten
Journal:  Obstet Gynecol       Date:  2012-12       Impact factor: 7.661

3.  Histotype-genotype correlation in 36 high-grade endometrial carcinomas.

Authors:  Lien N Hoang; Melissa K McConechy; Martin Köbel; Guangming Han; Marjan Rouzbahman; Ben Davidson; Julie Irving; Rola H Ali; Sam Leung; Jessica N McAlpine; Esther Oliva; Marisa R Nucci; Robert A Soslow; David G Huntsman; C Blake Gilks; Cheng-Han Lee
Journal:  Am J Surg Pathol       Date:  2013-09       Impact factor: 6.394

4.  Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation.

Authors:  D T Wheeler; K A Bell; R J Kurman; M E Sherman
Journal:  Am J Surg Pathol       Date:  2000-06       Impact factor: 6.394

5.  HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.

Authors:  Carl Morrison; Vanna Zanagnolo; Nilsa Ramirez; David E Cohn; Nicole Kelbick; Larry Copeland; G Larry Maxwell; Larry G Maxwell; Jeffrey M Fowler
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

6.  HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.

Authors:  W Glenn McCluggage; Lynette E Connolly; Hilary A McBride; Steve Kalloger; C Blake Gilks
Journal:  Histopathology       Date:  2012-01-17       Impact factor: 5.087

7.  Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.

Authors:  Anna Yemelyanova; Hongxiu Ji; Ie-Ming Shih; Tian-Li Wang; Lee-Shu-Fune Wu; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2009-10       Impact factor: 6.394

8.  Uterine papillary serous carcinoma: patterns of metastatic spread.

Authors:  B A Goff; D Kato; R A Schmidt; M Ek; J A Ferry; H G Muntz; J M Cain; H K Tamimi; D C Figge; B E Greer
Journal:  Gynecol Oncol       Date:  1994-09       Impact factor: 5.482

9.  Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a gynecologic oncology group study.

Authors:  R J Zaino; R J Kurman; V L Brunetto; C P Morrow; R C Bentley; J O Cappellari; P Bitterman
Journal:  Am J Surg Pathol       Date:  1998-11       Impact factor: 6.394

10.  Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma.

Authors:  Elke A Jarboe; Ellen S Pizer; Alexander Miron; Nick Monte; George L Mutter; Christopher P Crum
Journal:  Mod Pathol       Date:  2009-01-16       Impact factor: 7.842

View more
  9 in total

Review 1.  The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future.

Authors:  Emily A Goebel; August Vidal; Xavier Matias-Guiu; C Blake Gilks
Journal:  Virchows Arch       Date:  2017-12-12       Impact factor: 4.064

2.  Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups.

Authors:  Sara Imboden; Inti Zlobec; Tilman T Rau; Eva Bettschen; Carol Büchi; Lucine Christe; Amanda Rohner; Michael D Müller; Joseph W Carlson
Journal:  Mod Pathol       Date:  2020-07-29       Impact factor: 7.842

3.  Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer.

Authors:  Sònia Gatius; Mariona Jove; Cristina Megino-Luque; Manel Albertí-Valls; Andree Yeramian; Nuria Bonifaci; Miquel Piñol; Maria Santacana; Irene Pradas; David Llobet-Navas; Reinald Pamplona; Xavier Matías-Guiu; Núria Eritja
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

4.  Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.

Authors:  Shaomin Hu; Jeff L Hinson; Rahul Matnani; Michael L Cibull; Rouzan G Karabakhtsian
Journal:  Mod Pathol       Date:  2017-10-06       Impact factor: 7.842

5.  Serous carcinoma of the uterine cervix: Clinicopathological features differing from serous carcinomas of other female organs.

Authors:  Shoko Kitade; Kazuya Ariyoshi; Kenichi Taguchi; Shoji Maenohara; Yui Tomita; Kenzo Sonoda; Masao Okadome; Toshiaki Saito
Journal:  J Obstet Gynaecol Res       Date:  2019-10-22       Impact factor: 1.730

6.  What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience.

Authors:  Michalis Liontos; Anna Svarna; Charalampos Theofanakis; Oraianthi Fiste; Angeliki Andrikopoulou; Maria Kaparelou; Konstantinos Koutsoukos; Nikolaos Thomakos; Dimitrios Haidopoulos; Alexandros Rodolakis; Meletios Athanasios Dimopoulos; Flora Zagouri
Journal:  Curr Oncol       Date:  2021-11-20       Impact factor: 3.677

Review 7.  The Many Faces of Serous Neoplasms and Related Lesions of the Female Pelvis: A Review.

Authors:  Sameera Rashid; Maria A Arafah; Mohammed Akhtar
Journal:  Adv Anat Pathol       Date:  2022-05-01       Impact factor: 3.875

Review 8.  Endometrial stromal sarcoma in combination with mixed type endometrial carcinomas: A case report and literature review.

Authors:  Xiao-Xin Xiu; Hua-Li Wang; Lv Yun-Yi; Kong Fan-Dou; Hou Jin-Ping
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

9.  Evaluation of HER2/neu Expression in High-Grade Endometrial Carcinoma and Its Clinicopathological Correlation.

Authors:  Soheila Sarmadi; Narges Izadi-Mood; Nazanin Mansourzadeh; Dorna Motevalli
Journal:  Iran J Pathol       Date:  2019-09-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.